GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (FRA:0RY) » Definitions » Debt-to-Revenue

Rhythm Biosciences (FRA:0RY) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Rhythm Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Rhythm Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.02 Mil. Rhythm Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Rhythm Biosciences's annualized Revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.


Rhythm Biosciences Debt-to-Revenue Historical Data

The historical data trend for Rhythm Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Debt-to-Revenue Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Rhythm Biosciences's Debt-to-Revenue

For the Diagnostics & Research subindustry, Rhythm Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Debt-to-Revenue falls into.



Rhythm Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Rhythm Biosciences's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.053 + 0) / N/A
=N/A

Rhythm Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Rhythm Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (FRA:0RY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (FRA:0RY) Headlines

No Headlines